Skip to main content
. 2020 May 6;20:214. doi: 10.1186/s12872-020-01478-1

Table 1.

Characteristics of patients in the study.

AF (n = 24) nAF (n = 24) P value
Gender (m/f) 10/14 9/15 0.768
Age (years) 55.33 ± 7.88 54.58 ± 11.53 0.794
BMI 23.25 ± 2.82 23.48 ± 3.42 0.806
NYHA class (n, I/II/III/IV) 0/3/20/1 0/3/18/3 0.541
White cell (*10^9/L) 5.66 ± 1.77 5.99 ± 1.51 0.492
Neutrophil (*10^9/L) 3.51 ± 1.39 3.75 ± 1.14 0.521
Lymphocyte (*10^9/L) 1.44 ± 0.58 1.53 ± 0.55 0.611
Blood glucose (mmol/l) 6.01 ± 1.46 5.88 ± 1.98 0.799
TG (mmol/l) 1.55 ± 0.74 1.83 ± 1.91 0.542
TC (mmol/l) 3.90 ± 0.97 4.45 ± 1.26 0.115
HDL (mmol/l) 0.90 ± 0.16 1.07 ± 0.26 0.013
LDL (mmol/l) 2.49 ± 0.73 2.72 ± 0.76 0.319
CRP (mg/l) 11.04 ± 19.61 17.86 ± 38.43 0.442
ESR (mm/h) 34.61 ± 27.69 27.73 ± 26.11 0.396
NTproBNP (pg/ml) 4118.52 ± 5309.2 3061.83 ± 2997.09 0.408
EF (%) 52.17 ± 11.42 54.75 ± 9.06 0.599
RVD (mm) 15.92 ± 4.62 16.63 ± 2.80 0.524
LVD (mm) 47.96 ± 10.39 48.21 ± 8.93 0.929
LAD (mm) 48.88 ± 8.34 38.50 ± 8.70 0.004
RAD (mm) 48.50 ± 9.82 43.00 ± 8.48 0.043
Smoking (n, %) 7 (29.17%) 5 (20.83%) 0.505
Drinking (n, %) 2 (8.33%) 4 (16.67%) 0.383
Hypertension (n, %) 5 (20.83%) 5 (20.83%) 1
CHD (n, %) 7 (29.17%) 3 (12.5%) 0.155
Diabetes (n, %) 3 (12.5%) 0 (0%) 0.074
Digitalis (n, %) 20 (83.33%) 15 (62.5%) 0.104
Amiodarone (n, %) 3 (12.5%) 0 (0%) 0.074
ACEI (n, %) 2 (8.33%) 2 (8.33%) 1
ARB (n, %) 1 (4.16%) 1 (4.16%) 1
β-blocker (n, %) 12 (50%) 17 (70.83%) 0.140
Ca2+ antagonist (n, %) 12 (50%) 9 (37.5%) 0.383
Statin (n, %) 3 (12.5%) 3 (12.5%) 1

Abbreviations used in table 1: BMI body mass index, NYHA class New York Heart Association class, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein, CRP C-reactive protein, ESR erythrocyte sedimentation rate, NTproBNP N-terminal pro B-type-natriuretic peptide, EF ejection fraction, RVD right ventricular dimension, LVD left ventricular dimension, LAD left atrial dimension, RAD right atrial dimension, CHD coronary heart disease, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker